Citigroup
TARS icon

Citigroup’s Tarsus Pharmaceuticals TARS Stock Holding History

Citigroup’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,000
Closed -$836K – 5774
2024
Q1 		$836K Buy
+23,000
New +$676K ﹤0.01% 3172

Other funds holding TARS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Citigroup's TARS Position: Q3 2026 in Review

Citigroup reduced its Tarsus Pharmaceuticals (TARS) stake by 10% in Q3 2026, selling an estimated $489K and leaving 60,266 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2158.

Citigroup first reported a position in TARS in Q4 2020 and has held it in 24 quarters since. 143 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • Citigroup held 60,266 shares of Tarsus Pharmaceuticals worth $4.74M as of Q3 2026.
  • Citigroup sold 7,032 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $489K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2158 holding.
  • Citigroup first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • 143 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.